Bottom line
Is BBC a good fund? The bottom line
BBC is an actively managed technology sector ETF from Virtus.
Its expense ratio is 0.65% — about $65 a year on every $10,000 invested, cheaper than 63% of technology sector funds we track.
It returned +63.8% over one year, −4.3% a year over five years, +3.3% a year over ten (as of Dec 31, 2025, per its prospectus).
With $46.4 million in net assets and 132 holdings, its largest position is Dreyfus Government Cash Manage (3.5%) and the top 10 make up 14.3% of the portfolio.
What to watch
- 5-year return in the bottom quarter of its category
- Small fund ($46.4 million) — small funds are likelier to close
Updated Nov 19, 2026
What BBC invests in
The Virtus Biotech Clinical Trials ETF (formerly, Virtus LifeSci Biotech Clinical Trials ETF) (the Fund ) seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index (the Underlying Index ).
Under normal market conditions, the Fund will invest not less than 80% of its assets in component securities of the Underlying Index. The Underlying Index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ( lead drug ) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. The Underlying Index is sponsored by LifeSci Index Partners, LLC (the Index Provider ). The Index Provider utilizes a selection committee comprised of its employees (the Index Committee ) that is responsible, pursuant to the rules included in the methodology for the Underlying Index, for making certain determinations for the Underlying Index, as more fully described below. The Index Committee utilizes various public data sources to make determinations, including…
From the fund's prospectus (filed Feb 27, 2026).
BBC performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| BBC | +63.8% | −4.3% | +3.3% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What BBC costs
On a $10,000 investment, BBC's 0.65% expense ratio costs about $65 a year. The prospectus estimates $810 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
BBC top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Dreyfus Government Cash Manage | 3.48% |
| 2 | First Tracks Biotherapeutics Inc TRAX | 1.67% |
| 3 | Mbx Biosciences Inc MBX | 1.24% |
| 4 | Ataibeckley Inc ATAI | 1.23% |
| 5 | Monopar Therapeutics Inc MNPR | 1.21% |
| 6 | Definium Therapeutics Inc DFTX | 1.18% |
| 7 | Xencor Inc XNCR | 1.10% |
| 8 | Zenas Biopharma Inc ZBIO | 1.06% |
| 9 | Uniqure Nv QURE | 1.06% |
| 10 | Apogee Therapeutics Inc APGE | 1.02% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 14.3% of the fund. See all top 25 holdings and asset mix →